Literature DB >> 8623820

Change in serum beta-human chorionic gonadotropin after abortion with methotrexate and misoprostol.

M D Creinin1.   

Abstract

OBJECTIVE: The purpose of this study was to determine the normal beta-human chorionic gonadotropin change within 24 hours after a medical abortion. Because a medical abortion creates a "miscarriage," these data can represent the serum beta-human chorionic gonadotropin changes that would occur with a complete spontaneous abortion. Knowledge of normal beta-human chorionic gonadotropin changes after a spontaneous abortion may help to differentiate within a 24-hour period a complete from an incomplete spontaneous abortion or an ectopic pregnancy. STUDY
DESIGN: Data from recent trials that used methotrexate and misoprostol for abortion at < or = 56 day's gestation were reviewed. Patients from each of four trials were included in this analysis if (1) they received both methotrexate intramuscularly and misoprostol vaginally and (2) they had serum beta-human chorionic gonadotropin levels drawn on both the day of misoprostol administration and the next day.
RESULTS: The change in serum beta-human chorionic gonadotropin was evaluated in 86 patients. Subjects who had a complete abortion after receiving methotrexate and a single dose of misoprostol had a decline in serum beta- human chorionic gonadotropin of 66% +/- 8%. All other subjects had a decline of 25% +/- 19% (p=0.0001).
CONCLUSIONS: An aborting pregnancy, if the abortion has occurred, should have a beta-human chorionic gonadotropin decrease of at least 48% within approximately 24 hours. This decline, however, does not guarantee that the abortion is complete. A patient with a serum beta-human chorionic gonadotropin level that has not declined by a minimum of approximately 50% over 24 hours is unlikely to have a complete abortion.

Entities:  

Keywords:  Abortion, Drug Induced--complications; Abortion, Induced--complications; Americas; Biology; California; Clinical Research; Clinical Trials; Developed Countries; Diseases; Endocrine System; Family Planning; Fertility Control, Postconception; Gonadotropins; Gonadotropins, Chorionic; Hormones; Misoprostol--side effects; North America; Northern America; Physiology; Pregnancy Complications; Pregnancy, Ectopic; Prospective Studies; Prostaglandins; Prostaglandins, Synthetic; Research Methodology; Studies; United States

Mesh:

Substances:

Year:  1996        PMID: 8623820     DOI: 10.1016/s0002-9378(96)70463-5

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

1.  First-trimester medical abortion practices in Canada: National survey.

Authors:  Edith R Guilbert; Althea S Hayden; Heidi E Jones; Katharine O'Connell White; E Steven Lichtenberg; Maureen Paul; Wendy V Norman
Journal:  Can Fam Physician       Date:  2016-04       Impact factor: 3.275

2.  Management of first trimester pregnancy loss can be safely moved into the office.

Authors:  Jana L Allison; Rebecca S Sherwood; Danny J Schust
Journal:  Rev Obstet Gynecol       Date:  2011
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.